Seeking Alpha

Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug...

Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR)
From other sites
Comments (1)
  • fish4uinmd
    , contributor
    Comments (266) | Send Message
     
    Baxter is a great company which I have owned for over 20 years. This is but a bump in the road for them...I am proud to be a shareholder of a company that has helped countless people have a better quality of life.
    7 May 2013, 09:05 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs